Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Metastatic Breast Cancer With a Isolated Brain Progression 1Lymphoma 1Hodgkin Disease 1

Interventions

Cyclophosphamide 241Rituximab 223Etoposide 138Filgrastim 113Vincristine 112Doxorubicin 104Prednisone 90Cytarabine 90Methotrexate 79fludarabine phosphate 77Radiotherapy 76Peripheral Blood Stem Cell Transplantation 71Melphalan 71Busulfan 60Tacrolimus 48Dexamethasone 48Mycophenolic Acid 46Carmustine 46Granulocyte Colony-Stimulating Factor 44fludarabine 43Antilymphocyte Serum 40Ifosfamide 38sargramostim 34Whole-Body Irradiation 34Cyclosporine 33Bortezomib 32Gemcitabine 30Methylprednisolone 27Bendamustine Hydrochloride 27Lenalidomide 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma × Biosimilar Pharmaceuticals × Clear all
NCT00003820 2017-04-20

Rituximab in Treating Patients With Hodgkin's Lymphoma

Stanford University

Phase 2 Completed
39 enrolled 9 charts
Lymphoid

Hodgkin Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡